Specialty Pharmacy

Elranatamab is a B-cell maturation antigen (BCMA)-CD3-targeted bispecific antibody.

Promising data suggest triplet regimens may more effectively treat patients with unresected and metastatic intrahepatic cholangiocarcinoma.

Pharmacists are the premier medication experts within health care, who understand more about medication interactions than most physicians and have the unique ability to prevent complications, improve adherence, and save lives.

Teprotumumab is the first fully human IgG1 monoclonal antibody approved by the FDA for the treatment of thyroid eye disease at its source not just reducing the symptoms.

ART also results in a faster decay of plasma HIV RNA and increased HIV CD8+T cell immunity compared with the treatment alone, investigators found.

Study finds little evidence to support the long-standing recommendation that women with a first-degree family relative diagnosed with breast cancer should get screened 10 years earlier.

Pharmacy Times is gearing up for Kidney Week (Nov. 3-6) by learning about the pharmacological role of kidney care from the president of the American Society of Nephrology.

New evidence suggests that using artificial intelligence can help individualize diagnostics and protocols, including when women should get mammograms and what medications can best suit which people.

Epcoritamab is an investigational subcutaneous bispecific antibody being investigated for the treatment of adult patients with relapsed/refractory large B-cell lymphoma.

A compound often found in citrus fruits, nobiletin, could be a less toxic and more effective treatment for cholangiocarcinoma.

Camizestrant is a next-generation oral SERD and pure Erα antagonist that has demonstrated anti-cancer activity across a range of preclinical models, including in patients with ER-activating mutations.

Inflammation-based prognostic scores can be a valuable tool in assessing the overall survival of patients with intrahepatic cholangiocarcinoma.

Otilimab also inhibits the biological function of GM-CSF by blocking the interaction of GM-CSF with its cell surface receptor.

New clinical outcomes from BICSTaR study indicate sustained impact of the therapy for individuals with HIV.

Ozanimod is an oral, sphinogosine 1-phosphate (S1P) receptor modulator that binds with high affinity to S1P receptors 1 and 5.

By 2019, lung cancer mortality rates decreased by 5.4% in males since 2015, while deaths from ovary cancer have also declined rapidly over the past 2 decades.

The indication is approved under accelerated approval based on response rate, and continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Research suggests that positron emission tomography scans are effective at detecting early and late Hodgkin’s lymphoma, and the results could help manage and reduce toxicity from current chemotherapies.

In a multivariable analysis, treatment with carboplatin is favored for extensive-stage cell lung cancer, even if it is not found to increase overall survival compared to standard care.

These study findings may have implications for monitoring for the development of ICANS in patients receiving CAR T-cell therapies for cancer, according to the authors.

Expanding capacity of health care outcomes statutes aims to link specialists with general practices.

Automation can lessen the administrative burden on providers and accelerate specialty prescribing and dispensing to provide patients with quality care the moment they need it.

The approval includes a novel dose and schedule of the combination, with a single dose of both drugs followed by durvalumab every 4 weeks in patients with unresectable hepatocellular carcinoma.

Nivolumab may cut the risk of death or recurrent cancer by more than half, according to phase 3 trial results.

A more comprehensive body of regulations is required to achieve consistency and safety for patients.

However, lack of access and awareness about pre-exposure prophylaxis, medication cost, and underestimating disease risk are all barriers to PrEP.

Investigators examined the impact of daily oral tenofovir disoproxil fumarate in combination with emtricitabine to see the effect on the microbiota in South African women.

Sonidegib binds to and inhibits a transmembrane protein to disrupt hedgehog pathway signal transduction and leading to antitumor activity in patients with locally advanced basal cell carcinoma.

Deutetrabenazine is the only VMAT2 inhibitor approved by the FDA for the treatment of tardive dyskinesia in adults and for the treatment of chorea associated with Huntington disease.

Rachel K. Anderson, PharmD, CSP, clinical program manager at Alliance Rx Walgreens Pharmacy, discusses the impact pharmacists have on the care journey for patients with multiple myeloma.